- Home
- RYTM vs FHI Comparison
RYTM vs FHI Comparison
Compare RYTM & FHI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RYTM
- FHI
- Stock Information
- Founded
- RYTM 2008
- FHI 1955
- Country
- RYTM United States
- FHI United States
- Employees
- RYTM N/A
- FHI N/A
- Industry
- RYTM Biotechnology: Pharmaceutical Preparations
- FHI Investment Managers
- Sector
- RYTM Health Care
- FHI Finance
- Exchange
- RYTM Nasdaq
- FHI Nasdaq
- Market Cap
- RYTM 5.9B
- FHI 3.4B
- IPO Year
- RYTM 2017
- FHI N/A
- Fundamental
- Price
- RYTM $85.63
- FHI $49.20
- Analyst Decision
- RYTM Strong Buy
- FHI Hold
- Analyst Count
- RYTM 13
- FHI 7
- Target Price
- RYTM $89.77
- FHI $42.57
- AVG Volume (30 Days)
- RYTM 969.0K
- FHI 514.2K
- Earning Date
- RYTM 08-05-2025
- FHI 07-31-2025
- Dividend Yield
- RYTM N/A
- FHI 2.76%
- EPS Growth
- RYTM N/A
- FHI 2.09
- EPS
- RYTM N/A
- FHI 3.58
- Revenue
- RYTM $136,863,000.00
- FHI $1,659,262,000.00
- Revenue This Year
- RYTM $37.47
- FHI $5.75
- Revenue Next Year
- RYTM $71.16
- FHI $3.82
- P/E Ratio
- RYTM N/A
- FHI $13.78
- Revenue Growth
- RYTM 48.88
- FHI 2.19
- 52 Week Low
- RYTM $40.61
- FHI $31.94
- 52 Week High
- RYTM $94.80
- FHI $49.70
- Technical
- Relative Strength Index (RSI)
- RYTM 64.42
- FHI 74.88
- Support Level
- RYTM $84.22
- FHI $48.46
- Resistance Level
- RYTM $92.14
- FHI $49.70
- Average True Range (ATR)
- RYTM 2.77
- FHI 0.76
- MACD
- RYTM -0.70
- FHI 0.14
- Stochastic Oscillator
- RYTM 13.33
- FHI 85.00
About RYTM Rhythm Pharmaceuticals Inc.
Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. It is engaged in the development and commercialization of therapies for patients with rare diseases. The company is focused on its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. Geographically the company generates its revenue from the United States and internationally with the majority being generated from the United States.
About FHI Federated Hermes Inc.
Federated Hermes provides asset-management services for institutional and individual investors. The firm had $800 billion in managed assets at the end of September 2024, composed of equity (10%), multi-asset (less than 1%), fixed-income (12%), alternative (3%), and money market (74%) funds. The firm's cash-management operations are expected to generate around 51% of Federated's revenue this year, compared with 29%, 12%, and 7%, respectively, for the equity, fixed-income, and alternatives/multi-asset operations. The company's products are distributed via trust banks, wealth managers, and retail broker/dealers (65% of AUM), institutional investors (26%), and international clients (9%).